KoBioLabs Surges on Celltrion Deal...ECM Boosters Gain Traction [K-bio pulse]
[Kim Jinsoo, Edaily Reporter] On the 25th, KoBioLabs' stock price reached the daily upper limit among pharmaceutical and biotech companies.
KoBioLabs drew significant attention after out-licensing three microbiome therapeutics to Celltrion, a leading biotechnology company in South Korea.
Following this, GC Wellbeing saw its stock price rise after announcing the launch of an extracellular matrix (ECM) based skin booster, which has recently emerged as a major market trend.
뉴스픽의 주요 문장 추출 기술을 사용하여 “이데일리” 기사 내용을 3줄로 요약한 결과입니다. 일부 누락된 내용이 있어 전반적인 이해를 위해서는 본문 전체 읽기를 권장합니다.
